Category
Osteopore (ASX:OSX) has been green lit by Hong Kong’s Medical Device Control System (MDACS), offering the bone healing specialist the perfect staging ground into Greater China.
In a major new development, bone healing company Osteopore (ASX:OSX) has been granted a patent in China for its ‘smart’ 3D biometric scaffolds.
Medical technology company Singular Health has partnered with innovative Australian scientific research agency CSIRO, on a project that is looking to develop an artificial intelligence-based tool to automatically design replacement “cranial implants” for 3D printing. The company has also entered into a collaboration with ASX-listed Osteopore to validate results of the project.
Medical technology company Osteopore (ASX: OSX) says the “robust capital position” it ended the June quarter in will enable it to take advantage of an expected increase in elective surgeries.
A recent article published in the Advance Science magazine discussed research by Monash University that uncovered a new technique to alter the shape of individual stem cells, which could potentially speed up recovery times for bone replacements.
Australian-Singaporean bioresorbable implants manufacturer Osteopore has announced a partnership with SingHealth to establish the company’s first Global Centre of Excellence (GCoE) for customised medical devices.
Australian-Singaporean regenerative medicine company Osteopore Limited (ASX: OSX; Osteopore or Company) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to partner with SingHealth, under the auspices of A.L.I.C.E@SGH Campus to establish Osteopore’s first Global Centre of Excellence (GCoE) for customised medical devices.
Bone specialist Osteopore (ASX:OSX) has signed a Memorandum of Understanding (MOU) with China-based medical device innovation accelerator InnoVentures to commercialise Osteopore’s orthopaedic products in China.
Osteopore (OSX) and CellHeal have signed a binding term sheet to collaborate with a view to commercialising the use of Osteopore’s regenerative implant technology in China, Hong Kong, Macau, and Taiwan.
Osteopore’s bioresorbable mesh product, Osteomesh®, has received reimbursement approval from Discovery Health Medical Scheme (DHMS). Following its partnership with South African distributor Chronos Medical (Pty) Ltd, Osteopore is now aiming to incorporate more of its products into the DHMS reimbursement scheme, following regulatory approval.
With an initial three-year term, Majeton will immediately begin engaging with doctors and hospitals, both government and private. Osteopore aims to continue expanding its network to enable greater accessibility to a wider range of products targeting the Singapore dental and oral maxillofacial market.
Osteopore (ASX: OSX) signs two initial agreements with Accelerate Technologies Pte Ltd (A*STAR’s technology transfer arm) to license innovative bioactive technology designed to accelerate bone and tissue regeneration, for Osteopore’s incorporation into implants.
Osteopore (ASX: OSX) announces a strategic sub-distribution partnership with Kelyniam through its U.S. sales distribution partner, Bioplate Inc. to further penetrate the USD1.1 billion cranial implant market.
Osteopore shares digitalisation initiatives to increase efficiency.
Regenerative implant innovators Osteopore and plastic and reconstructive surgeon Dr Michael Wagels have teamed up to conduct two ground-breaking human clinical trials.
After revolutionising reconstructive surgeries with regenerative implants that promote natural bone healing and tissue repair, Osteopore International is globalising its devices for broader use in dental, orthopaedic and spinal surgeries.
Medtech company Osteopore (ASX: OSX) will soon have it’s 3D-printed bone regeneration products in the view of major international medical markets through a new collaboration with one of the world’s largest medical companies.
Regenerative medicine specialist Osteopore (ASX: OSX) is set to help relieve the knee pain of thousands of sufferers with the company now able to use several of its procedures in Singapore and Vietnam.
Target Market Determination as of 13th March 2024